Losartan improves erectile dysfunction in diabetic patients: A clinical trial

International Journal of Impotence Research

Volumn 24, Issue 6, 2012, Pages 217-220

  Chen, Y ^a   Cui, S ^a   Lin, H ^a   Xu, Z ^a   Zhu, W ^a   Shi, L ^a   Yang, R ^a   Wang, R ^b   Dai, Y ^a  

^a NANJING UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

angiotensin type 1 receptor blocker; diabetes; erectile dysfunction; losarton; PDE5 inhibitor

Indexed keywords

LOSARTAN; TADALAFIL;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE SEVERITY; DIZZINESS; DRUG HYPERSENSITIVITY; EPISTAXIS; ERECTILE DYSFUNCTION; GLOBAL ASSESSMENT QUESTION; HEADACHE; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUAL INTERCOURSE; SPERMATOZOON PENETRATION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARBOLINES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; HUMANS; LOSARTAN; MALE; MIDDLE AGED; PATIENT SATISFACTION; PENILE ERECTION; PHOSPHODIESTERASE 5 INHIBITORS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84869229601     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2012.4     Document Type: Article

References (20)

1. Chen Y, Dai Y, Wang R. Treatment strategies for diabetic patients suffering from erectile dysfunction. Expert Opin Pharmacother 2008; 9: 257-266. (Pubitemid 351233733)
2. Moore CR, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl 2006; 8: 675-684. (Pubitemid 44869615)
3. Israilov S, Shmuely J, Niv E, Engelstein D, Livne P, Boniel J. Evaluation of a progressive treatment program for erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2005; 17: 431-436.
4. Behrend L, Vibe-Petersen J, Perrild H. Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction. Int J Impot Res 2005; 17: 264-269. (Pubitemid 40675510)
5. Blonde L. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebocontrolled trials. Curr Med Res Opin 2006; 22: 2111-2120. (Pubitemid 44789975)
6. Chen Y, Li SX, Yao LS, Wang R, Dai YT. Valsartan treatment reverses erectile dysfunction in diabetic rats. Int J Impot Res 2007; 19: 366-370. (Pubitemid 47026077)
7. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997; 157: 1920-1925. (Pubitemid 27171811)
8. Yang R, Yang B, Wen Y, Fang F, Cui S, Lin G et al. Losartan, an angiotensin type I receptor, restores erectile function by downregulation of cavernous reninangiotensin system in streptozocin-induced diabetic rats. J Sex Med 2009; 6: 696-707.
9. Ertemi H, Mumtaz FH, Howie AJ, Mikhailidis DP, Thompson CS. Effect of angiotensin II and its receptor antagonists on human corpus cavernous contractility and oxidative stress: modulation of nitric oxide mediated relaxation. J Urol 2011; 185: 2414-2420.
10. Abdel Aziz MT, El Asmer MF, Mostafa T, Atta H, Mahfouz S, Fouad H et al. Effects of losartan, HO-1 inducers or HO-1 inhibitors on erectile signaling in diabetic rats. J Sex Med 2009; 6: 3254-3264.
11. Llisterri JL, Lozano Vidal JV, Argaya Roca M, Pol Bravo C, Sanchez Zamorano MA. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336-341. (Pubitemid 32428834)
12. Düsing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003; 2: 29-34. (Pubitemid 38112142)
13. Baumhäkel M, Schlimmer N, Böhm M. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res 2008; 20: 493-500.
14. Montorsi F, Verheyden B, Meuleman E, Jünemann KP, Moncada I, Valiquette L et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004; 45: 339-344, discussion 344-345.
15. Porst H, Giuliano F, Glina S, Ralph D, Casabé AR, Elion-Mboussa A et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, doubleblind, placebo-controlled trial. Eur Urol 2006; 50: 351-359. (Pubitemid 44038075)
16. Porst H, Glina S, Ralph D, Zeigler H, Wong DG, Woodward B. Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. J Sex Med 2010; 7: 3487-3494.
17. Liau CS, Lee CM, Sheu SH, Ueng KC, Chien KL, Su TC et al. Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential Hypertension in chinese patients. Clin Drug Investig 2005; 25: 473-479.
18. Fusco F, Razzoli E, Imbimbo C, Rossi A, Verze P, Mirone V. A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition. BJU Int 2010; 105: 1634-1639.
19. De Young LX, Domes T, Lim K, Carson J, Brock GB. Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. Eur Urol 2008; 54: 213-220.
20. Kovanecz I, Rambhatla A, Ferrini MG, Vernet D, Sanchez S, Rajfer J et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2008; 101: 203-210. (Pubitemid 350294044)